Emma Walmsley, GlaxoSmithKline CEO (Fang Zhe/Xinhua/Alamy Live News)

Glax­o­SmithK­line places a risky bet on Ar­row­head­'s RNA drug in the fail­ure-strewn NASH field

As ac­tivist in­vestors champ at the bit for change at drug gi­ant Glax­o­SmithK­line, the phar­ma gi­ant has turned over many rocks to find an R&D suc­cess to present to its de­trac­tors. In NASH, a field strewn with fail­ures, GSK hopes a new li­cense deal can churn out a much-need­ed win­ner.

GSK will pay $120 mil­lion in up­front cash and $910 mil­lion in down­stream mile­stones to de­vel­op and sell ARO-HSD, Ar­row­head Phar­ma­ceu­ti­cals’ RNA in­ter­fer­ence drug tar­get­ing fat­ty liv­er dis­ease non­al­co­holic steato­hep­ati­tis (NASH), the com­pa­nies said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA